Phase 2
Completed N=116
Evaluation of the Precision and Sensitivity of Tilmanocept Uptake Value (TUV) on Tc 99m Tilmanocept Planar Imaging
Source: ClinicalTrials.gov NCT03938636 ↗Enrolled (actual)
116
Serious AEs
1.7%
Results posted
Aug 2023
Primary outcomePrimary: Arms 1 & 2: Assess Camera-specific Precision of TUV — 0.159; 0.067; 0.091; 0.124 Pixel intensity
Summary
This clinical trial will look at scans of the hands and wrists taken from healthy control subjects (HCs) and from subjects with rheumatoid arthritis (RA). Before each scan, subjects will be given an injection of Tc 99m tilmanocept to help the scan identify inflammation in the hand and wrist joints, which can be a part of the RA disease. Data from the scans will be used to calculate a number referred to as tilmanocept uptake value (or TUV) that is a measure of how much Tc 99m tilmanocept has located in the joints. The questions this trial aims to answer are:
* How consistent are the scan results (TUVs) when the scans are repeated over time?
* What are normal TUVs in healthy people? This will help define abnormally high values in people with RA.
* Are TUVs calculated early after a person starts a new drug to treat RA able to predict whether that person will have a good response to the drug later on (after it has had time to take full effect several weeks later)?
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Arms 1 & 2: Assess Camera-specific Precision of TUV |
0.159; 0.067; 0.091; 0.124; 0.087; 0.125 | — |
| PRIMARY Arms 1 and 2: Stability of the Mean/Variance Relationship |
263.31; 208.79; 16.92295; 13.189704; 19.613096; 20.477108 | — |
| PRIMARY Arm 3: Correlation of ΔTUVglobal[5w] and Response to Therapy |
0.248; 0.238; 0.115; 0.121; 0.165; 0.154 | — |
| PRIMARY Longitudinal (8-day) Variation of TUV |
0.135; 0.151; 0.221; 0.179; 0.235; 0.263 | — |
| SECONDARY Arm 1 Normal Ranges of TUVjoint |
1.01; 1.20; 1.05; 1.33; 0.85; 0.92 | — |
| SECONDARY Qualitative Evaluations of SPECT/CT as an Indication of Bone Involvement Rather Than Localization Within the Synovial Space in the Hands and Wrists of Arm 2 Subjects |
— | — |
| SECONDARY Arm 3 (Correlation of TUVglobal[Baseline] and Response to Therapy) |
-0.045; 0.072; -0.100; -0.067; -0.086; 0.130 | — |
Eligibility Criteria
Inclusion Criteria
ALL SUBJECTS:
- The subject has provided written informed consent with HIPAA (Health Information Portability and Accountability Act) authorization before the initiation of any study-related procedures.
- ARMS 1 and 2 (only): The subject has agreed to not engage in any diet, lifestyle, or medication changes until study completion.
HEALTHY CONTROL SUBJECTS
- The subject is between 18 and 80 years of age at the time of consent.
- The subject is deemed to be clinically free of any inflammatory disease(s) and has not experienced joint pain for at least 28 days prior to the consent date.
- The subject is not currently on anti-inflammatory drugs (including NSAIDs) and has not taken anti-inflammatories for at least 28 days prior to the consent date.
- For all ongoing concomitant medications, the subject has maintained a stable dose for at least 28 days prior to the consent date.
CLINICALLY DIAGNOSED ACTIVE RA SUBJECTS:
- The subject is at least 18 years of age and was ≥ 18 years of age at the time of RA diagnosis.
- The subject has moderate to severe RA as determined by the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Classification Criteria (score of ≥ 6/10).
- The subject has a 28-joint disease activity score (DAS28) of ≥ 3.2 (includes the Erythrocyte Sedimentation Rate [ESR] test and Visual Analog Scale [VAS]).
- Subjects receiving traditional DMARDs must have been on therapy for ≥ 90 days and at a stable dose for ≥ 30 days prior to the first imaging visit (Day 0).
- If the subject is receiving bDMARD or janus kinase (JAK) inhibitor therapy, they have been at a stable dose > 180 days prior to the first imaging visit (Day 0).
- If the subject is receiving NSAIDs or oral corticosteroids, the dose has been stable for > 28 days prior to first imaging visit (Day 1). The corticosteroid dose must be ≤ 10 mg/day of prednisone or an equivalent steroid dose.
- ARM 3 (only): The subject is receiving anti-rheumatic treatment and is a candidate for initiation of, or change to, a new anti-TNFα bDMARD treatment.
Exclusion Criteria
- The subject is pregnant or lactating.
- The subject size or weight is not compatible with imaging per the investigator.
- The subject has had or is currently receiving radiation therapy or chemotherapy.
- The subject has renal insufficiency as demonstrated by a glomerular filtration rate of < 60 mL/min.
- The subject has hepatic insufficiency as demonstrated by ALT (alanine aminotransferase [SGPT]) or AST (aspartate aminotransferase [SGOT]) greater than 3 times the upper limit of normal.
- The subject has any severe, acute, or chronic medical conditions and/or psychiatric conditions and/or laboratory abnormalities that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration that would deem the subject inappropriate for study participation.
- The subject has a known allergy to or has had an adverse reaction to dextran exposure.
- The subject has received an investigational product within 30 days prior to the Tc 99m tilmanocept administration.
- The subject has received intra-articular corticosteroid injections ≤ 8 weeks prior to the first imaging visit (Day 0).
- The subject has received any radiopharmaceutical within 7 days or 10 half-lives prior to the administration of Tc 99m tilmanocept.
Data sourced from ClinicalTrials.gov (NCT03938636). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.